Novo Nordisk A/S (NYSE:NVO) was upgraded by equities research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Friday, MarketBeat Ratings reports.

Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Tuesday, October 10th. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. BNP Paribas cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Finally, Bank of America upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $55.00.

Novo Nordisk A/S (NVO) traded up $0.22 during trading hours on Friday, hitting $51.99. 1,551,783 shares of the stock were exchanged, compared to its average volume of 2,101,519. Novo Nordisk A/S has a twelve month low of $32.83 and a twelve month high of $52.32. The company has a market cap of $101,280.00, a PE ratio of 22.67, a P/E/G ratio of 3.10 and a beta of 0.65.

In related news, insider Eric S. Sprott acquired 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $8.34 per share, with a total value of $417,000.00.

Several institutional investors have recently made changes to their positions in NVO. Proficio Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 6.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock valued at $111,000 after purchasing an additional 150 shares during the last quarter. AlphaMark Advisors LLC raised its position in shares of Novo Nordisk A/S by 1.1% in the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock valued at $113,000 after purchasing an additional 30 shares during the last quarter. MUFG Americas Holdings Corp raised its position in shares of Novo Nordisk A/S by 100.0% in the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock valued at $129,000 after purchasing an additional 1,500 shares during the last quarter. Zions Bancorporation raised its position in shares of Novo Nordisk A/S by 677.1% in the 3rd quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock valued at $137,000 after purchasing an additional 2,485 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Novo Nordisk A/S by 44.4% in the 2nd quarter. Parallel Advisors LLC now owns 4,108 shares of the company’s stock valued at $174,000 after purchasing an additional 1,264 shares during the last quarter. 6.17% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Novo Nordisk A/S (NVO) Stock Rating Upgraded by Morgan Stanley” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/novo-nordisk-as-nvo-stock-rating-upgraded-by-morgan-stanley.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.